x
Filter:
Filters applied
- Psoriasis
- Griffiths, Christopher EMRemove Griffiths, Christopher EM filter
- BADBIRRemove BADBIR filter
Publication Date
Please choose a date range between 2017 and 2018.
Author
- Ashcroft, Darren M3
- Reynolds, Nick J3
- Warren, Richard B3
- Lunt, Mark2
- Smith, Catherine H2
- Barker, Jonathan1
- Baudry, David1
- Bloem, Karien1
- Burden, A David1
- Cordingley, Lis1
- Dand, Nick1
- Duckworth, Michael1
- Emsley, Richard1
- Evans, Ian1
- Iskandar, Ireny YK1
- Mason, Kayleigh J1
- McElhone, Kathleen1
- Murphy, Ruth1
- Ormerod, Anthony D1
- Pushpa-Rajah, Angela1
- Rispens, Theo1
- Smith, Catherine1
- Stocken, Deborah1
- Thorneloe, Rachael J1
Keyword
- CI4
- confidence interval4
- British Association of Dermatologists Biologic Interventions Register3
- hazard ratio2
- HR2
- PASI2
- Psoriasis Area and Severity Index2
- TNFI2
- 75% improvement in baseline Psoriasis Area and Severity Index1
- 90% improvement in baseline Psoriasis Area and Severity Index1
- ADA1
- AE1
- Biomarkers of Systemic Treatment Outcomes in Psoriasis1
- British Association of Dermatologists Biologic Interventions Registry1
- BSTOP1
- IBD1
- IMID1
- IQR1
- LPA1
- OR1
- PASI751
- PASI901
- PSOLAR1
- Psoriasis Longitudinal Assessment and Registry1
Psoriasis
4 Results
- Original Article Clinical Research: TherapeuticsOpen Access
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study
Journal of Investigative DermatologyVol. 139Issue 1p115–123Published online: August 18, 2018- Nina Wilkinson
- Teresa Tsakok
- Nick Dand
- Karien Bloem
- Michael Duckworth
- David Baudry
- and others
Cited in Scopus: 46Biologics have transformed management of inflammatory diseases. To optimize outcomes and reduce costs, dose adjustment informed by circulating drug levels has been proposed. We aimed to determine the real-world clinical utility of therapeutic drug monitoring in psoriasis. Within a multicenter (n = 60) prospective observational cohort, 544 psoriasis patients were included who were receiving adalimumab monotherapy and had at least one serum sample and Psoriasis Area and Severity Index (PASI) score available within the first year. - Original Article Clinical Research: Patient OutcomesOpen Access
Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength
Journal of Investigative DermatologyVol. 138Issue 4p785–794Published online: November 25, 2017- Rachael J. Thorneloe
- Christopher E.M. Griffiths
- Richard Emsley
- Darren M. Ashcroft
- Lis Cordingley
- on behalf of the British Association of Dermatologists Biologic Interventions Register
- and others
Cited in Scopus: 36Medication non-adherence is a missed opportunity for therapeutic benefit. We assessed “real-world” levels of self-reported non-adherence to conventional and biologic systemic therapies used for psoriasis and evaluated psychological and biomedical factors associated with non-adherence using multivariable analyses. Latent profile analysis was used to investigate whether patients can be categorized into groups with similar medication beliefs. Latent profile analysis categorizes individuals with similar profiles on a set of continuous variables into discrete groups represented by a categorical latent variable. - Original Article Clinical Research: Patient OutcomesOpen Access
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Journal of Investigative DermatologyVol. 138Issue 4p775–784Published online: October 25, 2017- Ireny Y.K. Iskandar
- Richard B. Warren
- Mark Lunt
- Kayleigh J. Mason
- Ian Evans
- Kathleen McElhone
- and others
Cited in Scopus: 62Little is known about the drug survival of second-line biologic therapies for psoriasis in routine clinical practice. We assessed drug survival of second-line biologic therapies and estimated the risk of recurrent discontinuation due to adverse events or ineffectiveness in patients with psoriasis who had failed a first biologic therapy and switched to a second in a large, multicenter pharmacovigilance registry (n = 1,239; adalimumab, n = 538; etanercept, n = 104; ustekinumab, n = 597). The overall drug survival rate in the first year after switching was 77% (95% confidence interval = 74–79%), falling to 58% (55–61%) in the third year. - Original Article Clinical ResearchOpen Access
Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Journal of Investigative DermatologyVol. 138Issue 3p534–541Published online: October 17, 2017- Zenas Z.N. Yiu
- Catherine H. Smith
- Darren M. Ashcroft
- Mark Lunt
- Shernaz Walton
- Ruth Murphy
- and others
Cited in Scopus: 51Serious infection is a concern for patients with psoriasis receiving biologic therapies. We assessed the risk of serious infections for biologics used to treat psoriasis by comparison with a cohort receiving non-biologic systemic therapies in a propensity score-weighted Cox proportional hazards model using data from the British Association of Dermatologists Biologic Interventions Register. Overall, 1,352; 3,271; and 994 participants were included in the etanercept, adalimumab, ustekinumab cohorts, respectively, and 3,421 participants were in the non-biologic cohort.